A discourse of non-alcoholic steatohepatitis

Abstract

 Non-alcoholic fatty liver disease (NAFLD) is a major cause of chronic liver disease and a worldwide public health concern with a prevalence of 25%.¹ The highest recorded prevalence (32%) is found in the Middle East, followed by South America (31%), Asia (27%), the United States of America (USA) (24%), Europe (23%) and Africa (14%).² By 2030, 400 million people worldwide will be affected by NAFLD in Europe, the USA, and Asia. The incidence of the disease in China has recently exceeded that of the USA and Europe.³ China will have the greatest growth in NAFLD patients worldwide by 2030, with 314.58 million individuals affected.⁴ A term recently developed, metabolic dysfunction-associated fatty liver disease (MAFLD), highlights diagnostic characteristics, such as obesity, type II diabetes, and insulin resistance, which are favourable for the development of this disease.